405 related articles for article (PubMed ID: 15531493)
1. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
6. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
[TBL] [Abstract][Full Text] [Related]
9. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
10. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
Zitzmann M; Nieschlag E
J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
[TBL] [Abstract][Full Text] [Related]
12. Which testosterone replacement therapy?
Cantrill JA; Dewis P; Large DM; Newman M; Anderson DC
Clin Endocrinol (Oxf); 1984 Aug; 21(2):97-107. PubMed ID: 6467640
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
[TBL] [Abstract][Full Text] [Related]
14. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
[TBL] [Abstract][Full Text] [Related]
15. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
[TBL] [Abstract][Full Text] [Related]
16. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth.
Butler GE; Sellar RE; Walker RF; Hendry M; Kelnar CJ; Wu FC
J Clin Endocrinol Metab; 1992 Jul; 75(1):37-44. PubMed ID: 1619029
[TBL] [Abstract][Full Text] [Related]
17. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
18. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate.
Partsch CJ; Weinbauer GF; Fang R; Nieschlag E
Eur J Endocrinol; 1995 Apr; 132(4):514-9. PubMed ID: 7711892
[TBL] [Abstract][Full Text] [Related]
19. Effects of various modes of androgen substitution therapy on erythropoiesis.
Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
Behre HM; Abshagen K; Oettel M; Hübler D; Nieschlag E
Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]